These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 10028630)

  • 1. Exposure of critical groups to nuclear medicine patients.
    Mountford PJ; O'Doherty MJ
    Appl Radiat Isot; 1999 Jan; 50(1):89-111. PubMed ID: 10028630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is it safe to work with iodine-131 if you are pregnant? A risk assessment for nuclear medicine staff involved with cleaning and decontamination.
    Barber RW; Parkin A; Goldstone KE
    Nucl Med Commun; 2003 May; 24(5):571-4. PubMed ID: 12717076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk assessment of the nuclear medicine patient.
    Mountford PJ
    Br J Radiol; 1997 Jul; 70(835):671-84. PubMed ID: 9245878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Examination of occupational exposure to medical staff (primarily nurses) during 131I medical treatments].
    Watanabe M; Ishikawa N; Ito K; Ito K
    Kaku Igaku; 2004 Feb; 41(1):25-31. PubMed ID: 15171456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiation dose rates from adult patients undergoing nuclear medicine investigations.
    Mountford PJ; O'Doherty MJ; Forge NI; Jeffries A; Coakley AJ
    Nucl Med Commun; 1991 Sep; 12(9):767-77. PubMed ID: 1945188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Radiation exposure of the families of outpatients treated with radioiodine (iodine-131) for hyperthyroidism.
    Barrington SF; O'Doherty MJ; Kettle AG; Thomson WH; Mountford PJ; Burrell DN; Farrell RJ; Batchelor S; Seed P; Harding LK
    Eur J Nucl Med; 1999 Jul; 26(7):686-92. PubMed ID: 10398815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetal dose estimates and the ICRP abdominal dose limit for occupational exposure of pregnant staff to technetium-99m and iodine-131 patients.
    Mountford PJ; Steele HR
    Eur J Nucl Med; 1995 Oct; 22(10):1173-9. PubMed ID: 8542902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safe radiation exposure of medical personnel by using simple methods of radioprotection while administering 131I-lipiodol therapy for hepatocellular carcinoma.
    Garin E; Laffont S; Rolland Y; Olivie D; Lecloirec J; Herry JY; Boucher E; Raoul JL; Bourguet P
    Nucl Med Commun; 2003 Jun; 24(6):671-8. PubMed ID: 12766603
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Release of patients after therapy with unsealed radionuclides.
    International Commission on Radiological Protection
    Ann ICRP; 2004; 34(2):v-vi, 1-79. PubMed ID: 15571759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Minimizing nuclear medicine technologist radiation exposure during 131I-MIBG therapy.
    Turpin BK; Morris VR; Lemen L; Weiss BD; Gelfand MJ
    Health Phys; 2013 Feb; 104(2 Suppl 1):S43-6. PubMed ID: 23287519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation dose produced by patients during radiopharmaceutical incorporation in nuclear medicine diagnostic procedures.
    Morán V; Prieto E; García-García B; Barbés B; Ribelles MJ; Richter JÁ; Martí-Climent JM
    Rev Esp Med Nucl Imagen Mol; 2016; 35(3):175-85. PubMed ID: 26750552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation protection issues associated with nuclear medicine out-patients.
    Thomson WH; Harding LK
    Nucl Med Commun; 1995 Nov; 16(11):879-92. PubMed ID: 8587752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose to fingertips of staff preparing stranded iodine-125 seeds for permanent prostate implants.
    van Haaren PM; van't Riet A; Moerland MA; Koedooder C; Westendorp H
    Radiat Prot Dosimetry; 2011 Apr; 145(1):61-5. PubMed ID: 21112885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TEDE per cumulated activity for family members exposed to adult patients treated with 131I.
    Han EY; Lee C; Bolch WE
    Radiat Prot Dosimetry; 2013; 153(4):448-56. PubMed ID: 22821723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the Point-Source Method for Estimating Dose Rates to Members of the Public from Exposure to Patients with 131I Thyroid Treatment.
    Dewji SA; Bellamy M; Hertel N; Leggett R; Sherbini S; Saba M; Eckerman K
    Health Phys; 2015 Sep; 109(3):233-41. PubMed ID: 26222218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation using an advanced extremity gamma instrumentation system of options for shielding the hand during the preparation and injection of radiopharmaceuticals.
    Whitby M; Martin CJ
    J Radiol Prot; 2003 Mar; 23(1):79-96. PubMed ID: 12729420
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Radiation exposure in the environment of patients after application of radiopharmaceuticals. Part 2: Therapeutic procedures].
    Sudbrock F; Boldt F; Kobe C; Hammes J; Eschner W; Schicha H
    Nuklearmedizin; 2009; 48(1):17-25. PubMed ID: 19212607
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Internal exposure monitoring of 131I-radiopharmaceutical production workers in Iran.
    Alirezazadeh N; Garshasbi H; Karimi Diba J
    Radiat Prot Dosimetry; 2003; 104(2):173-6. PubMed ID: 12918795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nuclear medicine annual external occupational dose distribution: Rio de Janeiro, Brazil, year 2005.
    Mauricio CL; Lima AL; da Silva HL; Souza-Santos D; Silva CR
    Radiat Prot Dosimetry; 2011 Mar; 144(1-4):510-4. PubMed ID: 21051433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The patient as a radioactive source: an intercomparison of survey meters for measurements in nuclear medicine.
    Uhrhan K; Drzezga A; Sudbrock F
    Radiat Prot Dosimetry; 2014 Nov; 162(1-2):101-4. PubMed ID: 25071244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.